Dutasteride: Clinically Proven BPH Symptom Relief
| Product dosage: 0.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.63 | $49.02 (0%) | 🛒 Add to cart |
| 60 | $1.55 | $98.04 $92.88 (5%) | 🛒 Add to cart |
| 90 | $1.52 | $147.06 $136.74 (7%) | 🛒 Add to cart |
| 120 | $1.50 | $196.08 $180.60 (8%) | 🛒 Add to cart |
| 180 | $1.49 | $294.12 $268.32 (9%) | 🛒 Add to cart |
| 270 | $1.48
Best per pill | $441.18 $399.04 (10%) | 🛒 Add to cart |
Dutasteride is a prescription medication specifically formulated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. As a potent 5-alpha-reductase inhibitor, it works by systematically reducing dihydrotestosterone (DHT) levels, the primary hormonal driver of prostate growth. This targeted action leads to a significant decrease in prostate volume, alleviating urinary obstruction and improving bothersome lower urinary tract symptoms. Clinical studies demonstrate its efficacy in reducing the risk of acute urinary retention and the need for prostate-related surgery, making it a cornerstone in the long-term management of BPH.
Features
- Contains 0.5 mg of the active pharmaceutical ingredient dutasteride
- Available in soft gelatin capsules for oral administration
- Formulated with butylated hydroxytoluene and gelatin among inactive ingredients
- Manufactured under strict pharmaceutical quality control standards
- Requires prescription and medical supervision for use
Benefits
- Significantly reduces prostate size, alleviating pressure on the urethra
- Improves urinary flow and reduces hesitancy, straining, and weak stream
- Decreases the frequency of nocturia and urinary urgency
- Lowers the risk of acute urinary retention episodes
- Reduces the probability of requiring BPH-related surgical intervention
- Provides sustained symptom control with once-daily dosing
Common use
Dutasteride is primarily indicated for the management of symptomatic benign prostatic hyperplasia in adult males. It is prescribed for patients with moderate to severe symptoms who have demonstrated prostate enlargement. The medication is typically used as a long-term treatment rather than for immediate symptom relief, with maximum therapeutic effects generally observed after 3-6 months of continuous therapy. It may be used as monotherapy or in combination with alpha-blockers for enhanced symptomatic improvement in appropriate patients.
Dosage and direction
The recommended dosage is one 0.5 mg capsule taken orally once daily, with or without food. Patients should swallow the capsule whole and not crush or chew it. Consistency in administration time is recommended to maintain stable drug levels. Treatment response should be assessed periodically, and therapy continues as long as therapeutic benefit persists. Dosage adjustment is not typically required for elderly patients or those with renal impairment, but caution is advised in hepatic impairment. Patients should be informed that several months of treatment may be needed before symptomatic improvement becomes apparent.
Precautions
Patients should be advised that dutasteride is contraindicated in women and children. Men taking dutasteride should not donate blood until at least 6 months after their final dose to prevent administration to a pregnant female transfusion recipient. Regular digital rectal examinations and other evaluations for prostate cancer should continue as dutasteride reduces PSA levels by approximately 50% after 6 months of treatment, requiring adjustment in the interpretation of this screening parameter. Hepatic function should be monitored in patients with pre-existing liver disease. Patients should be counseled about the potential sexual side effects and the slow onset of therapeutic effect.
Contraindications
Dutasteride is contraindicated in women who are or may become pregnant due to the risk of fetal harm, specifically abnormalities of the external genitalia in male fetuses. It is also contraindicated in pediatric patients and individuals with known hypersensitivity to dutasteride, other 5-alpha-reductase inhibitors, or any component of the formulation. The medication should not be used in patients with severe hepatic impairment unless the potential benefit justifies the potential risk.
Possible side effects
The most commonly reported adverse reactions include erectile dysfunction (4-5%), decreased libido (3-4%), ejaculation disorders (1-2%), and breast enlargement and tenderness (1-2%). These effects typically persist throughout treatment but may resolve in some patients with continued therapy. Less frequent side effects may include dizziness, headache, and rash. Although rare, allergic reactions including lip swelling and pruritus have been reported. Patients should be monitored for the possibility of depression, though a causal relationship has not been definitively established.
Drug interaction
Formal drug interaction studies have shown no clinically significant interactions with warfarin, digoxin, or cholestyramine. However, concomitant administration with potent CYP3A4 inhibitors such as ritonavir, ketoconazole, or erythromycin may increase dutasteride concentrations. Similarly, medications that significantly induce CYP3A4 activity might reduce dutasteride exposure. Concurrent use with other 5-alpha-reductase inhibitors is not recommended due to the potential for additive effects. Alpha-adrenergic blockers may be used concomitantly, but patients should be monitored for potential additive blood pressure effects.
Missed dose
If a dose is missed, patients should take it as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistent daily dosing is important for maintaining therapeutic effect, but occasional missed doses are unlikely to significantly impact long-term treatment outcomes.
Overdose
In case of suspected overdose, symptomatic and supportive measures should be instituted. There is no specific antidote for dutasteride overdose. Dutasteride is highly protein-bound, so dialysis is unlikely to be beneficial. Single doses up to 40 mg have been administered without significant adverse effects, though higher doses might potentially increase the incidence and severity of side effects. Medical attention should be sought immediately in cases of accidental ingestion by women or children.
Storage
Store at room temperature between 15°C and 30°C (59°F and 86°F). Keep the medication in its original container to protect from light and moisture. Do not store in bathroom cabinets where humidity levels fluctuate. Keep out of reach of children and pets to prevent accidental ingestion. Do not use beyond the expiration date printed on the packaging. Proper disposal of unused medication is recommended to prevent environmental contamination or accidental exposure.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Dutasteride is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to treatment may vary, and patients should consult their physician for personalized medical advice. The complete prescribing information should be reviewed before initiating therapy. Patients should report any adverse effects to their healthcare provider promptly.
Reviews
Clinical trials demonstrate that approximately 70% of patients experience significant improvement in BPH symptoms after 6 months of dutasteride therapy. Urologists report consistent reduction in prostate volume of 20-30% within 6-12 months of treatment. Patient satisfaction surveys indicate improved quality of life scores related to urinary symptoms in the majority of long-term users. The CombAT study showed combination therapy with dutasteride and tamsulosin provided superior symptom improvement compared to monotherapy with either agent. Real-world evidence supports the long-term safety profile observed in clinical trials with sustained efficacy over 4 years of treatment.